Inhibition of FGFR3 and treatment of multiple myeloma

Details for Australian Patent Application No. 2004289672 (hide)

International Classifications

Event Publications

27 April 2006 PCT application entered the National Phase

PCT publication WO2005/047244 Priority application(s): WO2005/047244

30 October 2008 Alteration of Name

The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

20 November 2008 Alteration of Name

The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

24 June 2010 Application Accepted

Published as AU-B-2004289672

12 August 2010 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 20 Jul 2010. Address for service in Australia - FB Rice & Co Level 23 44 Market Street Sydney NSW 2000

2 December 2010 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 20 Jul 2010

9 December 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.